Catheter Precision, Inc. Receives Chinese Patent for LockeT

Catheter Precision, Inc. (VTAK:NYSE/American) has announced the issuance of its first LockeT patent in China. The company, based in Fort Mill, South Carolina, focuses on developing advanced cardiac electrophysiology products.

LockeT is a suture retention device designed for closing percutaneous catheter access sites during various procedures. It is currently available in the US and select international markets. The company expects CE mark certification by the first quarter of 2025, which would allow access to European markets.

David Jenkins, CEO of Catheter Precision, highlighted China's significant market potential for LockeT. He emphasized its low cost, ease of application, patient comfort, and benefits for patient management, such as early ambulation and same-day discharge.